Comparison of volume doses from conventional two-dimensional brachytherapy with corresponding doses from three-dimensional magnetic resonance imaging-based brachytherapy in carcinoma cervix
Conclusion: Conventional X-ray-based plans with moderate Point A doses deliver HRCTV D90 comparable to MRI-based plans in patients with no residual disease, and centrally placed residual disease, provided proper applicator placement and ideal geometry can be ensured. Soft-tissue image-based BT dose optimization ought to be considered in all patients with gross residual disease at the time of brachytherapy.
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Susan Mathews M Biju Azariah Seetha Mohandas Sharika V Menon Preethi George PG Jayaprakash Source Type: research
More News: Bladder Cancer | Brachytherapy | Cancer | Cancer & Oncology | Carcinoma | Cervical Cancer | Colorectal Cancer | Men | MRI Scan | Statistics | Study